GTHA – GeneThera, Inc.
Stock Guru Profile GeneThera, Inc. (OTCBB:GTHA)
CashFlowNews.com reports that negative EBITDA for GeneThera Inc (OTC:GTHA) for its twelve months ended September 30, 2006 was $(934,261), a 63% improvement over the year earlier same twelve months when Gene Thera generated $(2,503,861) in negative EBITDA. EBITDA for the most recent twelve months also reached a two year high.For Gene Thera’s quarter ended September 30, 2006 EBITDA was $(485,041), compared with $(230,655), a 110% deterioration over the comparable year earlier quarter. Gene Thera has generated three consecutive quarters of negative EBITDA.
EBITDA for the most recent quarter also reached a four year low.The shares of Gene Thera were recently trading at $0.04.EBITDA defined by CashFlowNews.com:EBITDA (Earnings Before Interest Taxes Depreciation and Amortization) is calculated by taking Operating Income and adding or subtracting depreciation and/or amortization.CashFlowNews.com is the primary “cash flow” news source for over 10,000 public companies, monitoring and reporting on EBITDA, Cash Flow from Operations (CFFO) and Free Cash Flow (FCF).CashFlowNews also features cash flow related stories from other sources such as financial magazines, news letters and rating services, etc. For more information on how to subscribe to CashFlowNews.com e-mail cashflownews@baystreet.com.
SOURCE: GeneThera, Inc., and Stock Diagnostics
CONTACT: GeneThera, Inc.
Dr. Tony Milici, 303-463-6371
http://www.genethera.net
GeneThera and the Road to Italy/on the Road to Italy
Dr. Tony Milici
Chairman of the Board, President & CEO
Source:
GTHA – GeneThera, Inc.
Dr. Antonio Milici, CEO
GeneThera, Inc.
3930 Youngfield St.
Wheat Ridge, CO 80033
Fax: (303) 463 – 6377
About GeneThera, Inc.:
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The company’s proprietary diagnostic solution is based on a genetic expression assay, GEA(tm), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne’s Disease, diseases affecting cattle worldwide.
About Tecan:
Tecan ( http://www.tecan.com ) is a leading player in the Life Science supply industry that specializes in the development, production, and distribution of solutions enabling the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Through its subsidiary REMP ( http://www.remp.com ), Tecan is a leading supplier of compound and sample storage, managerial and logistic solutions. Tecan clients are leading pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories.
Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2005, Tecan achieved sales of CHF 344.9 million (USD 275.9 million; EUR 222.5 million). Registered shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN / Reuters: TECZn.S / Valor: 1210019).
“Safe Harbor” Statement: Certain statements in this release are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company’s ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
Forward Loooking Statement: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Disclosure: Pentony Enterprises LLC was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment advisers or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. Pentony Enterprises no longer holds shares.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .